Markers of platelet activation and oxidant stress in atherothrombotic disease

Thrombosis and Haemostasis

Volumn 78, Issue 1, 1997, Pages 280-284

  FitzGerald, Garret A ^a,b   Tigges, Jessica ^a   Barry, Patricia ^a   Lawson, John A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Department of Biochemistry and Biophysics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIOXIDANT; MARKER;

ALCOHOL CONSUMPTION; ATHEROSCLEROSIS; BLOOD CLOTTING; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CONFERENCE PAPER; DISEASE PREDISPOSITION; HEREDITY; HUMAN; HYPERHOMOCYSTEINEMIA; OXIDATIVE STRESS; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOGENESIS; THROMBOSIS;

EID: 0030839065     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657540     Document Type: Conference Paper

References (68)

1. Ossei-Gerning N, Mansfield MW, Stickland MH, Wilson IJ, Grant PJ. Plasminogen activator inhibitor-1 promoter 4 G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thomb Vase Biol 1997;17:33-37.
2. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997;349:385-388.
3. Newman PJ. Platelet alloantigens: cardiovascular as well as immunological risk factors. Lancet 1997;349:370-371.
4. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
5. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994;344:973-795.
6. Stemler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J. Clin Invest 1993;91:308-318.
7. Frei B, Forte TM, Ames BN, Cross CCE. Gas phase oxidants of cigarette smoke induce lipid peroxidation and changes in lipoprotein properties in human blood plasma. Biochem J 1991;277:133-138.
8. Meagher EA., Lucey M., Bensinger S, FitzGerald GA. Alcohol induced formation of 8-epi PGF2a, and index of oxidant stress in vivo. J. Invest Med 1996;44:223.
9. Stephens NG, Parson A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ, Brown MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) Lancet 1996;347:781-786.
10. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner, B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993;328; 1444-1449.
11. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary disease in men. N Engl J Med 1993;328:1450-1456.
12. Coller BS, ang D, Scudder LE. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. Circulation 1997;95:860-867.
13. Patrono C. Unstable coronary artery disease: need for long-term antithrombotic treatment? Aspirin alone may not be the ideal antitithrombotic strategy, but that's what we have adequate trial data for. Cardiovas Res 1997;5008:1-2.
14. Kereiakes DJ, Runyon JP, Kleiman NS, Higby NA, Anderson LC, Hantsbarger G, McDonald S, Anders RJ. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab administration for complex coronary intervention. Circulation 1996;94:906-910.
15. Théroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis J-F, Nasmith J, Fung AY, Boudrenault J-R, Delage F, Dupuis R, Kells C, Bokslag M, Steiner B, Rapold HJ. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study. Circulation 1996;94:899-905.
16. Nowak J, Murray JJ, Oates JA, FitzGerald GA. Biochemical evidence of a chronic abnormality in platelet and vascular function in apparently healthy chronic cigarette smokers. Circulation 1987;76:6-14.
17. Meade TW, Vickers MV, Thompson SG, Stirling Y, Haines AP, Miller GJ. Epidemiological characteristics of platelet aggregability. Br Med J 1985;290:428.
18. FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ, Brash AR. Endogenous synthesis of prostacyclin and thromboxane and platelet function during chronic aspirin administration in man. J Clin Invest 1983;71:676-688.
19. Savi P, Laplace MC, Maffrand JP, Herbert JM. Binding of [3H]-2-methylthio ADP to rat platelets: effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther 1994;269:772-777.
20. Gold HK, Gimple LW, Yasuda T, Leinbach RC, Werner W, Holt R, Jordan R, Berger H, collen D, Coller BS. Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 1990;86:651-659.
21. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet Therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308:81-106.
22. More RS, Chauhan A. Antiplatelet rather than anticoagulant therapy with coronary stenting. Lancet (Editorial) 1997;349:146-147.
23. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 1996;348:1329-1339.
24. Topol EJ, Califf RM, Weisman FH et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin fro reduction of clinical restenosis: results at six months. Lancet 1994;343:881-886.
25. FitzGerald GA. Modern drug therapy: Dipyridamole. N Engl J Med 1987;316:1247-1257.
26. Muller TH, Su CAPF, Weisenberg H,m Brickl R, Nehmiz G, Eisert WG. Dipyridamole alone or combined with low-dose actyl-salicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br J Clin Pharm 1990;30:179-186.
27. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurological Sci 1996;143:1-13.
28. Abrams CS, Ellison N, Budzynski AZ, Shattil SJ. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990;75:128-138.
29. Michelson AD, Barnard MR, Hechtman, HB, MacGregor H, connolly RJ, Loscalzo J, Valeri CR. In vitro tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin, but continue to circulate and function. Proc Natl Acad Sci USA 1996;93:11877-11882.
30. Abrams C, Shattil SJ. Immunological detection of activated platelets in clinical disorders. Thromb Haemostasis 1991;65: 467-473.
31. Scharf RE, Tomer A, Marzee UM, Teirstein PS, Ruggeri ZM, Harker LA. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection. Arteriosclerosis and Thrombosis 1992;12:1475-1487.
32. Humbert M, Nurden P, Bihour C, Pasquet J-M, Winckler J, Heilmann E, Savi P, Herbert J-M, Kunicki TJ, Nurden AT. Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. Arteroscler Thromb Vasc Biol 1996;16:1532-1543.
33. Patrono, C, Ciabattoni G, Pugliese F, Pierucci A, Blair IA, FitzGerald GA. Estimated rate of thromboxane secretion into the circulation of normal man. J Clin Invest 1986;77:590-594.
34. 2: An index of thromboxane formation in the human circulation. Proc Natl Acad. Sci USA. 1986;83: 5861-5865.
35. Reilly IAG, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987;69:180-186.
36. 2 using bonded-phase phenylboronic acid columns and capillary gas chromatography-negative-ion chemical ionization mass spectrometry. Analyt Biochem 1985;150:463-470.
37. Catella F, FitzGerald GA. Paired analysis of urinary thromboxane B2 metabolites in humans. Throm. Research 1987;47:647-656.
38. Fitzgerald DJ, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N. Engl. J. Med. 1986;315:983-989.
39. Fitzgerald DJ, Catella F, Roy L, FitzGerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988;77:142-150.
40. FitzGerald GA, Pedersen,AK, Patrono C. Analysis of prostacyclin and thromboxane A2 biosynthesis in cardiovascular disease (editorial). Circulation 1983;67: 1174-1177.
41. Cominacini L, Pastorino AM, Garbin U, et al. The susceptibility of low-density lipoprotein to in vitro oxidation is increased in hypercholesterolemic patients. Nutrition 1994;10:527-531.
42. Princen HMG, van Duyvenvoorde W, Buytenhek R, et al. Supplementation with low doses of vitamin E protects LDL from lipid peroxidation in men and women. Arterioscler Thromb Vasc Biol 1995;15:325-333.
43. McCormick ML, Beuttner GR, Britigan BE. The spin trap a-(4-Pyridyl-1-oxide)-N-tert-butylnitrone stimulates peroxidase-mediated oxidation of deferoxamine. Implications for pharmacological use of spin-trapping agents. J Biol Chem 1995;270:29265-26269.
44. Phillips DH, Hewer A, Martin CN, Garner RC, King MM. Correlation of DNA adduct level in human lung with cigarette smoking. Nature 1988;336:790-792
45. Loft S, Astrup A, Buemann B, Poulsen HE. Oxidative DNA damage correlates with oxygen consumption in humans. FASEB J 1994;8:534-537.
46. Leeuwenburgh C, Rasmussen JE, Hsu FF, Mueller DM, Pennathur S, Heinecke JW. Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. J Biol Chem 1997;272: 3520-3526.
47. Leeuwenburgh C, Hardy, MM, Hazen SL, Wagner P, Oh-ish S, Steinbrecher UP, Heinecke JW. Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. J Biol Chem 272;1433-1436.
48. O'Connor DE, Mihelich ED, Coleman MC. Sterochemical course of the antoxidative cyclization of lipid hydroperoxides to prostaglandin-like bicyclo endoperoxides. J Am Chem Soc 1987;106:3577-3584.
49. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990;87: 9383-9387.
50. 2-isoprostane) metabolites in human urine and plasma. J Biol Chem 1993;268:4161-4169.
51. 2a generation during coronary reperfusion: a potential quantitative marker of oxidant stress in vivo. Circulation 1997 (in press).
52. a, an index of oxidant stress, is increased during acute coronary angioplasty. Circulation 1996;94:3725 (abst).
53. 2a in familial hypercholesterolemia: Evidence of oxidative stress in vivo. Circulation 1996;94:3727 (abst).
54. Pratico D, Juliano J, Spagnvoli L, Mauriello A, Maclouf J, Violi F, FitzGerald GA. Monocytes in human atherosclerotic plaque contain high levels of 8-epi PGF2a in indices of oxidative stress in vivo. Circulation (abst) 1996;94:277.
55. ain human platelets. J Biol Chem 1995;270:9800-9808.
56. a by human monocytes: discriminant production by reactive oxygen species and PG G/H S-2. J. Biol. Chem. 1996;271:8919-8924.
57. Patrono C, FitzGerald GA. F2 isoprostanes in vivo: indices of oxidant stress in atherothrombotic disease. Arterioscler ThrombVasc Biol 1997 (in press).
58. Morrow JD, Frei B, Longmire AW, et al. Increase in circulating products of lipid peroxidation (F2-isoprostane) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 1995;332:1198-1203.
59. Reilly M, Delanty N, Lawson JA, FitzGerald GA. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 1996;94:19-25.
60. Levenson J, Giral P, Megnien JL, Gariepy J, Plainfosse M-C, Simon A. Fibrinogen and its relations to subclinical extracoronary and coronary atherosclerosis in hypercholesterolemic men. Arterioscler Thromb Vasc Biol 1997;17:45-50.
61. Kundsen L, Hasenkam JM, Kure HH, Hughes P, Bellaiche L, Ahlburg P, Djurhuus C. Monitoring thrombin generation with prothrombin fragment 1.2 assay during cardiopulmonary bypass surgery. Thromb Res 1996;84:45-54.
62. FitzGerald GA. The human pharmacology of thrombin inhibition. Coronary Artery Disease 1996;911-918.
63. Catella-Lawson F, FitzGerald GA. Confusion in reperfusion. Problems in the clinical development of antithrombotic drugs. Circulation 1997;95:793-795.
64. Leo R, Pratico D, Pulcinelli FM, Ghiselli A, Pignatelli P, colavita AR, Iuliano L, FitzGerald GA, Violi F. Platelet activation by superoxide anion and hydroxyl radicals intrinsically generated by platelets which had undergone anoxia and then reoxygenation. Circulation 1997;95:885-891.
65. Steinberg D. Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Circulation 1997;95:1062-1071.
66. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA 1996;93:2696-2701.
67. O'Brien KD, Alpers CE, Hokanson JE, Wang S, Chait A. Oxidation-specific epitopes in human coronary atherosclerosis are not limited to oxidized low-density lipoprotein. Circulation 1996;94:1216-1225.
68. Chaudhary AK, Nokubo M, Reddy GR, Yeola SN, Morrow J, Blair IA, Marnett LJ. Detection of endogenous malondialdehyde-deoxyguanosine adducts in human liver. Science 1994;265:1580-1582.